E. Ohman J or Asset Management AB Increases Stock Holdings in Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI)

E. Ohman J or Asset Management AB lifted its stake in Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) by 10.7% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 257,751 shares of the company’s stock after purchasing an additional 25,000 shares during the quarter. E. Ohman J or Asset Management AB’s holdings in Maravai LifeSciences were worth $1,405,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. JPMorgan Chase & Co. lifted its stake in shares of Maravai LifeSciences by 1,172.4% during the 3rd quarter. JPMorgan Chase & Co. now owns 4,050,245 shares of the company’s stock worth $33,658,000 after acquiring an additional 3,731,924 shares during the last quarter. Royce & Associates LP lifted its stake in shares of Maravai LifeSciences by 130.4% during the 3rd quarter. Royce & Associates LP now owns 908,778 shares of the company’s stock worth $7,552,000 after acquiring an additional 514,332 shares during the last quarter. Barclays PLC lifted its stake in shares of Maravai LifeSciences by 349.2% during the 3rd quarter. Barclays PLC now owns 184,189 shares of the company’s stock worth $1,531,000 after acquiring an additional 143,184 shares during the last quarter. Systematic Financial Management LP lifted its stake in shares of Maravai LifeSciences by 14.7% during the 3rd quarter. Systematic Financial Management LP now owns 1,612,161 shares of the company’s stock worth $13,397,000 after acquiring an additional 206,499 shares during the last quarter. Finally, Geode Capital Management LLC lifted its stake in shares of Maravai LifeSciences by 6.3% during the 3rd quarter. Geode Capital Management LLC now owns 2,752,077 shares of the company’s stock worth $22,874,000 after acquiring an additional 162,601 shares during the last quarter. Hedge funds and other institutional investors own 50.25% of the company’s stock.

Insider Transactions at Maravai LifeSciences

In related news, General Counsel Kurt Oreshack sold 25,000 shares of the business’s stock in a transaction on Friday, January 31st. The stock was sold at an average price of $5.03, for a total transaction of $125,750.00. Following the transaction, the general counsel now directly owns 167,618 shares in the company, valued at $843,118.54. The trade was a 12.98 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Carl Hull bought 175,000 shares of the company’s stock in a transaction that occurred on Monday, November 11th. The shares were acquired at an average price of $5.64 per share, for a total transaction of $987,000.00. Following the completion of the purchase, the insider now owns 175,000 shares in the company, valued at $987,000. The trade was a ∞ increase in their ownership of the stock. The disclosure for this purchase can be found here. Corporate insiders own 0.63% of the company’s stock.

Maravai LifeSciences Trading Up 3.6 %

MRVI opened at $4.94 on Thursday. The firm has a market cap of $1.25 billion, a price-to-earnings ratio of -3.01 and a beta of -0.08. The company has a current ratio of 10.74, a quick ratio of 9.94 and a debt-to-equity ratio of 0.89. Maravai LifeSciences Holdings, Inc. has a 12 month low of $4.28 and a 12 month high of $11.56. The stock has a fifty day moving average price of $5.38 and a 200-day moving average price of $7.06.

Maravai LifeSciences (NASDAQ:MRVI) last released its quarterly earnings results on Thursday, November 7th. The company reported ($0.09) EPS for the quarter. The company had revenue of $65.20 million during the quarter, compared to the consensus estimate of $67.58 million. Maravai LifeSciences had a negative return on equity of 6.61% and a negative net margin of 81.13%. During the same period in the previous year, the firm posted ($0.02) earnings per share. As a group, equities research analysts anticipate that Maravai LifeSciences Holdings, Inc. will post -0.24 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on the company. Guggenheim assumed coverage on Maravai LifeSciences in a research note on Thursday, December 19th. They set a “neutral” rating for the company. Wolfe Research assumed coverage on Maravai LifeSciences in a research report on Thursday, November 14th. They set a “peer perform” rating for the company. William Blair reaffirmed a “market perform” rating on shares of Maravai LifeSciences in a research report on Friday, November 8th. Royal Bank of Canada decreased their target price on Maravai LifeSciences from $17.00 to $13.00 and set an “outperform” rating for the company in a research report on Friday, November 8th. Finally, Robert W. Baird decreased their target price on Maravai LifeSciences from $10.00 to $9.00 and set an “outperform” rating for the company in a research report on Friday, November 8th. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $10.28.

About Maravai LifeSciences

Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company’s products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.